The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Expanding KRAS-targeted therapies with RMC compounds and pan-RAS inhibitors
Alexander Spira, MD, PhD, FACP, FASCO, NEXT Oncology Virginia, Fairfax, VA, comments on the growing interest in KRAS mutations as a target for cancer treatment, noting that recent discoveries such as RMC-6236 and RMC-9805 have shown promising results. Dr Spira highlights the potential of RAS-specific drugs, including pan-RAS inhibitors and RAS G12D drugs, which may benefit a significant proportion of patients with lung cancer, who account for approximately 40% of cases with KRAS mutations. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
